Generalized pustular psoriasis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

2 events
Mar 2024

Spevigo: FDA approved

treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg

FDAcompleted
Feb 2024Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

Shanghai Huaota Biopharmaceutical Co., Ltd. — PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

SPEVIGO

Boehringer Ingelheim

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Spevigo

(spesolimab-sbzo)Orphan drug

Boehringer Ingelheim Pharmaceuticals, Inc. (BI)

Interleukin-36 Receptor Antagonist [EPC]

12.1 Mechanism of Action Spesolimab-sbzo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 (IL-36) signaling by specif...

Approved Mar 2024FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial
1Phase 2
1Total recruiting
Search clinical trials for Generalized pustular psoriasis

Recent News & Research

No recent news articles indexed yet for Generalized pustular psoriasis.
Search PubMed for Generalized pustular psoriasis

Browse all Generalized pustular psoriasis news →

Specialist Network

Top 6 by expertise

View all Generalized pustular psoriasis specialists →

Quick Actions